论文部分内容阅读
目的分析N-乙酰半胱氨酸(NAC)联合孟鲁司特钠在治疗特发性肺纤维化中的疗效。方法 60例特发性肺纤维化诊断标准的患者,随机分为对照组和观察组,各30例。对照组给予泼尼松治疗,观察组在对照组基础上加用孟鲁司特钠和NAC治疗,分析对比两组患者治疗疗效。结果对照组中总有效率为63.3%,低于观察组的90.0%(P<0.05)。治疗后,观察组患者肺活量为(2.1±0.1)L、一氧化碳弥散量为(3.6±0.3)mmol/(min·k Pa),对照组患者肺活量为(2.0±0.1)L、一氧化碳弥散量为(3.5±0.1)mmol/(min·kPa);治疗后,观察组肺功能优于对照组,差异具有统计学意义(P<0.05)。结论 NAC联合孟鲁司特钠在治疗特发性肺纤维化中可有效控制患者的病情,在临床应用中值得进一步研究。
Objective To analyze the efficacy of NAC combined with montelukast sodium in the treatment of idiopathic pulmonary fibrosis. Methods Sixty patients with idiopathic pulmonary fibrosis diagnostic criteria were randomly divided into control group and observation group, with 30 cases in each group. The control group was given prednisone, and the observation group was treated with montelukast sodium and NAC on the basis of the control group. The curative effect of the two groups was compared and analyzed. Results The total effective rate was 63.3% in the control group, which was lower than 90.0% in the observation group (P <0.05). After treatment, the vital capacity in the observation group was (2.1 ± 0.1) L, the carbon monoxide diffusion volume was (3.6 ± 0.3) mmol / (min · kPa), the control group was (2.0 ± 0.1) L and the carbon monoxide diffusion volume was 3.5 ± 0.1) mmol / (min · kPa). After treatment, the lung function of the observation group was better than that of the control group (P <0.05). Conclusion NAC combined with montelukast sodium in the treatment of idiopathic pulmonary fibrosis can effectively control the patient’s condition, worthy of further study in clinical application.